X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (588) 588
humans (538) 538
kras mutations (457) 457
mutation (440) 440
oncology (431) 431
female (317) 317
male (307) 307
cancer (293) 293
kras mutation (276) 276
middle aged (273) 273
aged (254) 254
lung neoplasms - genetics (254) 254
adenocarcinoma (217) 217
lung cancer (215) 215
egfr (203) 203
adult (191) 191
genetic aspects (185) 185
chemotherapy (171) 171
lung neoplasms - pathology (169) 169
tumors (160) 160
aged, 80 and over (157) 157
pathology (156) 156
gefitinib (153) 153
adenocarcinoma - genetics (150) 150
ras proteins - genetics (150) 150
growth-factor receptor (148) 148
carcinoma, non-small-cell lung - genetics (145) 145
prognosis (143) 143
colorectal cancer (133) 133
proto-oncogene proteins - genetics (131) 131
metastasis (128) 128
proto-oncogene proteins p21 (126) 126
receptor, epidermal growth factor - genetics (120) 120
gene mutations (118) 118
lung neoplasms - drug therapy (118) 118
lung cancer, non-small cell (114) 114
respiratory system (113) 113
analysis (110) 110
care and treatment (105) 105
proto-oncogene proteins p21 - genetics (103) 103
research (101) 101
survival (101) 101
epidermal growth factor (100) 100
adenocarcinoma - pathology (96) 96
cell lung-cancer (96) 96
non-small cell lung cancer (92) 92
egfr mutations (90) 90
patients (89) 89
deoxyribonucleic acid--dna (86) 86
biomarkers, tumor - genetics (85) 85
acquired-resistance (84) 84
colorectal neoplasms - genetics (83) 83
health aspects (82) 82
neoplasm staging (81) 81
neoplasms (81) 81
carcinoma, non-small-cell lung - drug therapy (80) 80
cetuximab (80) 80
dna mutational analysis (78) 78
kras (78) 78
article (76) 76
carcinoma, non-small-cell lung - pathology (75) 75
kinases (74) 74
antineoplastic agents - therapeutic use (73) 73
digestive system diseases (73) 73
adenocarcinoma of lung (71) 71
cancer therapies (71) 71
egfr mutation (70) 70
retrospective studies (70) 70
lung adenocarcinoma (69) 69
tyrosine kinase inhibitors (69) 69
growth-factor-receptor (68) 68
cell biology (67) 67
erlotinib (67) 67
expression (67) 67
genes (67) 67
resistance (65) 65
therapy (64) 64
k-ras (63) 63
medical prognosis (63) 63
polymerase chain reaction (63) 63
gene-mutations (62) 62
nsclc (62) 62
respiratory tract diseases (62) 62
hematology, oncology and palliative medicine (61) 61
mutation - genetics (61) 61
carcinoma (60) 60
braf (59) 59
cell line, tumor (59) 59
gene (59) 59
immunohistochemistry (59) 59
protein kinase inhibitors - therapeutic use (56) 56
studies (56) 56
colorectal-cancer (55) 55
receptor, epidermal growth factor - antagonists & inhibitors (55) 55
animals (54) 54
colorectal neoplasms - pathology (53) 53
diagnosis (53) 53
medicine (53) 53
medicine & public health (53) 53
treatment outcome (53) 53
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Jhangiani, Shalini N and Sabo, Aniko and Mathew, Tittu and Ding, Li and Broderick, Stephen and Hanna, Megan and Zhao, Xiaojun and Zhang, Qunyuan and Tang, Yuzhu and Weinstock, George M and Hawes, Alicia C and Milosavljevic, Aleksandar and Scherer, Steven E and Ladanyi, Marc and Hall, Otis and Haipek, Carrie and Tonon, Giovanni and Crosby, Seth D and Yoshizawa, Akihiko and Koboldt, Daniel C and Lander, Eric S and Baldwin, Jennifer and Yao, Jiqiang and Fulton, Lucinda and Abbott, Rachel and Metcalf, Ginger A and Meyer, Rick and Sawyer, Christopher S and Shen, Hua and Zhu, Yiming and Dunford-Shore, Brian H and Winckler, Wendy and Dutt, Amit and Muzny, Donna M and Fewell, Ginger and Mardis, Elaine R and Fulton, Robert S and Meyerson, Matthew and Pohl, Craig and Miner, Tracie L and Gabriel, Stacey B and Larson, David E and Clerc, Kerstin and Schmidt, Heather and Province, Michael A and Thomas, Roman K and Getz, Gad and Beer, David G and Sander, Sacha and Travis, William D and Osborne, John R and Robinson, Jody and Orringer, Mark B and Ng, Brian and Chen, Ken and Kraja, Aldi and Ren, Yanru and Roth, Jack A and Sougnez, Carrie and McLellan, Michael D and Lawrence, Michael S and Wistuba, Ignacio I and Good, Peter J and Wheeler, David A and Morgan, Margaret B and Gonzalez-Garay, Manuel L and Zody, Michael C and Lin, Ling and Shi, Xiaoqi and Varmus, Harold E and Ziaugra, Liuda and Wilson, Richard K and Pao, William and Cibulskis, Kristian and Johnson, Bruce E and Weir, Barbara A and Fennell, Tim and Lewis, Lora R and Dooling, David J and Spitz, Margaret R and Chang, Andrew C and Vickery, Tammi and Gibbs, Richard A and Chirieac, Lucian R and Giordano, Thomas and Watson, Mark A and Onofrio, Robert C and Ozenberger, Bradley and Greulich, Heidi and Wendl, Michael C and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Institutionen för medicinsk biokemi och mikrobiologi and Uppsala universitet
Nature, ISSN 0028-0836, 10/2008, Volume 455, Issue 7216, pp. 1069 - 1075
Journal Article
Journal Article
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ISSN 0006-291X, 06/2018, Volume 501, Issue 1, pp. 253 - 258
High expression levels of survivin in KRAS-mutant lung adenocarcinomas are linked with unfavorable patient outcomes, suggesting that survivin is a promising... 
KRAS-mutant lung adenocarcinoma | RB1 | PATHWAYS | PROTEIN | BIOCHEMISTRY & MOLECULAR BIOLOGY | Survivin | COMBINATION | CANCER | p21 | Trametinib | FIBROBLASTS | EPITHELIAL-MESENCHYMAL TRANSITION | THERAPY | BIOPHYSICS | MEK INHIBITION | DEGRADATION | SENESCENCE
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2017, Volume 23, Issue 17, pp. 5101 - 5111
Journal Article
BMC Cancer, ISSN 1471-2407, 02/2018, Volume 18, Issue 1, pp. 157 - 8
Background: Diethylnitrosamine is a well known carcinogen that induces cancers of various organs in mice and rats. Using FVB/N mouse strain, here we show that... 
Mouse model | Tumorigenesis | NSCLC | Diethylnitrosamine | Lung cancer | N-NITROSODIETHYLAMINE | INITIATION | INDUCTION | CELL-CYCLE PROGRESSION | CANCER | TUMORS | EGFR | KRAS MUTATIONS | ONCOLOGY | NEVER SMOKERS | MICE | Adenocarcinoma | Rattus | Rats | Research | Nitrosoamines | Health aspects | Risk factors
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 06/2018, Volume 501, Issue 1, pp. 253 - 258
Journal Article
Cancer, ISSN 0008-543X, 03/2016, Volume 122, Issue 5, pp. 766 - 772
BACKGROUND The discovery of oncogenic drivers has ushered in a new era for lung cancer, but the role of these mutations in different racial/ethnic minorities... 
disparities | lung cancer | targeted therapy | genomics | race | CARBOPLATIN | SEX | EGFR MUTATIONS | SMOKING | CHEMOTHERAPY | PACLITAXEL | KRAS MUTATIONS | ONCOLOGY | FREQUENCY | Lung Neoplasms - ethnology | Adenocarcinoma - pathology | Adenocarcinoma of Lung | Receptor, ErbB-2 - genetics | Proto-Oncogene Proteins p21(ras) - genetics | United States | Humans | Middle Aged | ErbB Receptors - genetics | Lung Neoplasms - pathology | Male | Proto-Oncogene Proteins c-akt - genetics | MAP Kinase Kinase 1 - genetics | Young Adult | Brain Neoplasms - secondary | Ethnic Groups - genetics | Anaplastic Lymphoma Kinase | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Adenocarcinoma - ethnology | Liver Neoplasms - secondary | Lung Neoplasms - genetics | European Continental Ancestry Group - genetics | Hispanic Americans - genetics | Liver Neoplasms - genetics | Membrane Proteins - genetics | African Americans - genetics | Brain Neoplasms - genetics | Proto-Oncogene Proteins c-met - genetics | Liver Neoplasms - ethnology | Phosphatidylinositol 3-Kinases - genetics | Class I Phosphatidylinositol 3-Kinases | Asian Americans - genetics | Receptor Protein-Tyrosine Kinases - genetics | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Adolescent | Aged | Brain Neoplasms - ethnology | Care and treatment | Lung cancer | Genomics | Analysis | Health care disparities | Diagnosis | Research | Disparities | Lung Cancer | Targeted Therapy | Race
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2014, Volume 50, Issue 10, pp. 1819 - 1828
Abstract Background Platinum-based chemotherapy is the most common treatment in advanced-stage lung adenocarcinoma. Because the clinical significance of KRAS... 
Hematology, Oncology and Palliative Medicine | KRAS mutation | Advanced-stage lung adenocarcinoma | Platinum-based chemotherapy | Non-small cell lung cancer | PREDICTIVE MARKERS | SURVIVAL | 1ST-LINE CHEMOTHERAPY | PHASE-III | SMOKING | METASTATIC COLORECTAL-CANCER | K-RAS MUTATIONS | CETUXIMAB | ONCOLOGY | NEVER-SMOKERS | CELL | Smoking - adverse effects | Lung Neoplasms - drug therapy | Lung Neoplasms - ethnology | Multivariate Analysis | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Adenocarcinoma - pathology | Adenocarcinoma of Lung | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Patient Selection | Time Factors | DNA Mutational Analysis | Adult | Female | Adenocarcinoma - genetics | Retrospective Studies | Adenocarcinoma - ethnology | Lung Neoplasms - genetics | European Continental Ancestry Group - genetics | Genetic Predisposition to Disease | Risk Factors | Hungary - epidemiology | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Proto-Oncogene Proteins - genetics | Treatment Outcome | Chi-Square Distribution | Adenocarcinoma - drug therapy | Smoking - ethnology | Disease-Free Survival | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | Neoplasm Staging | Adenocarcinoma - mortality | Adenocarcinoma | Medical research | Care and treatment | Chemotherapy | Analysis | Medicine, Experimental | Genetic aspects | Cancer
Journal Article